Analyst firms · Raymond James · ALNY

Raymond James ALNY price target and rating history

Alnylam Pharmaceuticals Inc. (ALNY) · Health Care

Raymond James rates Alnylam Pharmaceuticals Inc. (ALNY) Outperform with a $315 price target, as of its latest action on Oct 30, 2026. It has published 4 rating actions on ALNY since September 2023, including 1 upgrade and 1 downgrade. Across 10 firms with a ALNY price target in the last 12 months, the median target is $324. Raymond James's $315 is 3% below that.

Current rating
Outperform
Price target
$315
Median target, all firms
$324
Actions on ALNY
4

Raymond James price target on ALNY

$420$314$208202420252026
Raymond James price target on ALNY, each point a stated target, September 2023 to October 2026.

Every Raymond James rating on ALNY

How other firms rate ALNY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Truist SecuritiesHold$225Nov 2, 2026
BernsteinMkt Perform$199Oct 30, 2026
Raymond JamesOutperform$315Oct 30, 2026
StifelHold$225Oct 29, 2026
UBSBuy$354Oct 15, 2026
BMO Capital MarketsOutperform$318Aug 19, 2026
CitigroupBuy$380May 19, 2026
JefferiesHold$330Mar 16, 2026
BarclaysOverweight$527Jan 28, 2026
OppenheimerOutperform$500Jan 7, 2026

Questions about Raymond James and ALNY

What is Raymond James's price target for ALNY?
Raymond James's latest stated price target for Alnylam Pharmaceuticals Inc. (ALNY) is $315, from its action on Oct 30, 2026.
What is Raymond James's rating on ALNY?
Raymond James rates ALNY Outperform, a bullish rating, as of Oct 30, 2026.
When did Raymond James last change its view on ALNY?
On Oct 30, 2026, Raymond James downgrades to Outperform from Strong Buy, price target $315.
How does Raymond James's ALNY target compare with other analysts?
Across 10 firms with a ALNY price target in the last 12 months, the median target is $324. Raymond James's $315 is 3% below that.

More ALNY rating histories

All Raymond James ratingsALNY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.